PTC Therapeutics, Inc. (PTCT)
Develops medicines for rare genetic and neurological disorders in children and adults.
$75.39-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+44.6%
The outlook
PTCT is trading near the middle of its 52-week range with analyst consensus leaning toward Buy. The average price target sits roughly 27% above the current price, though the stock is showing mixed momentum against its moving averages. Overall sentiment tilts bullish based on analyst ratings and valuation metrics.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 14 analysts
Price trendMixed vs its moving averages
52-week range68% of the way from its 52-week low to high
Price targetAvg target +27% vs current price
Analyst price target
~12-month · 14 analysts$96.07average target+27.4% vs now
Now $75.39
Low $70.00High $130.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.25B
52-wk high
$90.87
52-wk low
$43.18
50-day avg
$76.97
200-day avg
$72.96
Trailing P/E
—